These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9010039)

  • 1. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
    Bain C; Merrouche Y; Puisieux I; Blay JY; Negrier S; Bonadona V; Lasset C; Lanier F; Duc A; Gebuhrer L; Philip T; Favrot MC
    Br J Cancer; 1997; 75(2):283-6. PubMed ID: 9010039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Franzke A; Buer J; Probst-Kepper M; Lindig C; Framzle M; Schrader AJ; Ganser A; Atzpodien J
    Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
    Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
    Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose regimen of interleukin-2 for metastatic renal carcinoma.
    Sleijfer DT; Janssen RA; Willemse PH; Martens A; de Leij L; de Vries EG; Mulder NH
    Lancet; 1990 Jun; 335(8704):1522-3. PubMed ID: 1972445
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.
    van Bezooijen RL; Goey H; Stoter G; Hermans J; Fleuren GJ
    Cancer Immunol Immunother; 1996 Dec; 43(5):293-8. PubMed ID: 9024506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
    Martens A; Janssen RA; Sleijfer DT; Heijn AA; Mulder NH; The TH; de Leij L
    Br J Cancer; 1993 May; 67(5):1118-21. PubMed ID: 8494709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I expression in primary and metastatic renal cell carcinoma.
    Buszello H; Ackermann R
    Investig Urol (Berl); 1994; 5():55-9. PubMed ID: 7719321
    [No Abstract]   [Full Text] [Related]  

  • 9. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy.
    Mattijssen V; Van Moorselaar J; De Mulder PH; Schalkwijk L; Ruiter DJ
    J Immunother (1991); 1992 Jul; 12(1):64-9. PubMed ID: 1637784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
    Eklund JW; Kuzel TM
    Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
    Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
    Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
    Varga Z; de Mulder P; Kruit W; Hegele A; Hofmann R; Lamers C; Warnaar S; Mala C; Ullrich S; Mulders P
    Folia Biol (Praha); 2003; 49(2):74-7. PubMed ID: 12779016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
    Rini BI; Paintal A; Vogelzang NJ; Gajewski TF; Stadler WM
    J Immunother; 2002; 25(3):269-77. PubMed ID: 12000869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 based therapy for kidney cancer.
    Dutcher JP
    Cancer Treat Res; 2003; 116():155-72. PubMed ID: 14650831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.